Handbook of multiple sclerosis
By: edited by Stuart D. Cook.
Contributors: Cook, Stuart D.
Edition: 3rd ed.
Series: Neurological disease and therapy -- v. 53
Publisher: M. Dekker
Published: 2001
Place of publication: New York
Language: eng
Number of pages: 687
Subjects: Multiple Sclerosis
Notes: Includes bibliographical references and index.
Table of contents: title: part I. Etiopathogenesis. 1. The history of multiple sclerosis ; 2. The epidemiology of multiple sclerosis ; 3. The genetics of multiple sclerosis ; 4. Experimental models of virus-induced demyelination ; 5. Evidence for a viral etiology of multiple sclerosis ; 6. Experimental models of autoimmune demyelination ; 7. Evidence for immunopathogenesis ; 8. Autoantibodies in demyelinating disease; title: part II. Clinical pathologic features. 9. Clinical features ; 10. Cognitive impairment in multiple sclerosis ; 11. Loss and restoration of impulse conduction in disorders of myelin ; 12. Pathology of multiple sclerosis ; 13. Axonal injury in multiple sclerosis ; 14. Cerebrospinal fluid ; 15. Laboratory tests: evoked potentials ; 16. Neuroimaging and the use of magnetic resonance in multiple sclerosis; title: part III. Therapeutic considerations. 17. The natural history of multiple sclerosis ; 18. Prognostic factors in multiple sclerosis ; 19. Therapeutic considerations: rating scales ; 20. Therapeutic considerations: treatment of the acute exacerbation ; 21. Interferon-[beta]-1b: prophylactic therapy in multiple sclerosis ; 22. Therapeutic considerations: prophylactic therapy with interferon-[beta]-1a ; 23. Prophylactic therapy; title: glatiramer acetate (Copaxone) ; 24. Treatment of multiple sclerosis with intravenous immunoglobulin ; 25. Immunosuppressive drugs ; 26. Treatment of multiple sclerosis: bone marrow reconstitution, total lymphoid irradiation, and plasma exchange ; 27. Symptomatic therapy ; 28. Symptomatic treatment and rehabilitation in multiple sclerosis ; 29. Experimental therapies with T-cell vaccines, oral myelin, and monoclonal antibodies in multiple sclerosis ; 30. Future immunotherapies.